Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice-Reference-Cited by-同舟云学术

Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice

Published:2018-11 Issue: Volume:131 Page:53-65
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Morano Federica^ORCID,Sclafani Francesco

Funder

National Institute for Health Research (NIHR) Biomedical Research Centre (BRC)

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference77 articles.

1. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial;Adams;Lancet Oncol.,2011

2. An individual patient data (IPD) meta-analysis of the impact of thrombocytosis (?plts) on overall survival (OS) whilst using an intermittent chemotherapy (iCTx) strategy in advanced colorectal cancer (aCRC);Adams;J. Clin. Oncol.,2017

3. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study;Aranda;Eur. J. Cancer,2018

4. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9);Aparicio;J. Clin. Oncol.,2018

5. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials;Arnold;Ann. Oncol.,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis;NMR in Biomedicine;2023-04-18

2. Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review;Current Oncology Reports;2023-02-13

3. Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review;International Journal of Nanomedicine;2022-10

4. The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy;Frontiers in Pharmacology;2022-09-30

5. Preventive effects of Brassicaceae family for colon cancer prevention: A focus on in vitro studies;Biomedicine & Pharmacotherapy;2022-07